Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

Single-Dose, Randomized, Open-Label, Two-Way Crossover Study to Evaluate the Bioequivalence of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients Under Fasting or Postprandial Conditions

Trifluridine and Tipiracil Tablets is a nucleoside anti-metabolic and anti-cancer compound developed by Taiho (Dapeng) Co., Ltd., Japan, for the treatment of advanced colorectal cancer that inoperable resection, and progressed or relapsed after standard treatment. This study mainly evaluates bioequivalence, safety and tolerance of Trifluridine and Tipiracil Tablets in colorectal cancer patients.

Study Overview

• Status: Completed
• Conditions: Colorectal Cancer
• Intervention / Treatment: Drug: Trifluridine and Tipiracil Tablets; Drug: TAS-102

• Study Type: Interventional
• Enrollment (Actual): 64
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Shanxi
    • Xi'an, Shanxi, China, 710038
      • Tangdu hospital,fourth military medical university

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. 18-70 years old, life expectancy ≥ 3 months.
2. Histologically confirmed colon or rectal adenocarcinoma.
3. Has not received anti-tumor therapy before 4 weeks of first dose or Traditional Chinese Medicine anti-tumor therapy before 2 weeks of first dose.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
5. Has ability to take oral medication.

6. The main organs function are normally, the following criteria are met:

   1. Hemoglobin (HB) ≥ 100 g / L;
   2. Absolute neutrophil count (ANC) ≥1.5×109/L;
   3. Platelets (PLT) ≥ 80 × 109 / L;
   4. Total serum bilirubin (TBIL) ≤ 1.5 × ULN;
   5. Alanine transaminase (ALT) and Aspartate aminotransferase (AST) ≤ 2.5 × ULN (when the liver is invaded，AST ≤ 5×ULN);
   6. Serum creatinine ≤ 132.6 μmol / L.
7. Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ；No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization.
8. Understood and signed an informed consent form.

Exclusion Criteria:

1. Has serious diseases , including but not limited to:

   1. Has diagnosed and/or treated additional malignancy within 5 years prior to randomization. Exceptions include carcinoma in situ of cervix, non-melanoma skin cancer and superficial bladder tumor;
   2. Has brain metastases;
   3. Has active infection (such as infection caused body temperature ≥ 38 ° C);
   4. Has pleural effusion, pericardial effusion, or ascites requiring recurrent drainage before 4 weeks of first dose;
   5. Has intestinal obstruction, pulmonary fibrosis, renal failure, liver failure or symptomatic cerebrovascular disease;
   6. Has uncontrolled diabetes (fasting blood glucose (FBG) > 10mmol/L);
   7. Has myocardial infarction, severe/unstable angina pectoris, New York Heart Association (NYHA) grade III or IV symptomatic congestive heart failure within 12 months prior to first dose;
   8. Has gastrointestinal bleeding;
   9. Has HIV infection, or active hepatitis B or C;
   10. Has a history of organ transplants or autoimmune disease required immunosuppressive therapy;
   11. Has increased risk associated with participating in the study or taking the study drug, or mental disorders may interfere with the results of the study.

2. Has received any of the following treatments before the first dose:

   1. Has received partial or total gastrectomy;
   2. Has surgery (such as laparotomy, thoracotomy, and laparoscopic resection of the viscera and/or unhealed wounds) within 4 weeks;
   3. Has any study drug within 4 weeks.
3. Prior therapy with TAS-102.
4. Has adverse events caused by previous therapy except alopecia that did not recover to ≤ grade 2.
5. Pregnant or lactating woman.
6. Subjects who, in the opinion of the investigators, should not participate in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Trifluridine and Tipiracil Tablets	Drug: Trifluridine and Tipiracil Tablets; Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle
ACTIVE_COMPARATOR: TAS-102	Drug: TAS-102; TAS-102 given 20mg orally once under fasting or postprandial conditions per cycle

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC(0-infinity)	The AUC(0-infinity) is area under the serum concentration-time curve from time zero to infinite time.	3 days
AUC(0-t)	The AUC(0-t) is area under the serum concentration-time curve from time zero to t.	3 days
Bioequivalence based on Peak Plasma Concentration (Cmax)	The Cmax is observed maximum serum concentration, taken directly from the serum concentration-time profile	3 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Event	Security Index	Up to 4 weeks

Collaborators and Investigators

• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 21, 2019
• Primary Completion (ACTUAL): July 16, 2019
• Study Completion (ACTUAL): July 16, 2019

Study Registration Dates

• First Submitted: May 31, 2019
• First Submitted That Met QC Criteria: May 31, 2019
• First Posted (ACTUAL): June 5, 2019

Study Record Updates

• Last Update Posted (ACTUAL): April 19, 2022
• Last Update Submitted That Met QC Criteria: April 12, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Antimetabolites; Trifluridine
• Other Study ID Numbers: CTTQ-TAS-102-I-02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No